Starling Oncology (STLNW) Change in Accured Expenses (2020 - 2026)

Starling Oncology (STLNW) has reported Change in Accured Expenses for 7 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 1226.23% year-over-year to $3.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (down 52.41% YoY), and the FY2025 full-year result was -$448000.0, down 104.73% from the prior year.
• Change in Accured Expenses declined to $3.4 million in Q2 2026 per STLNW's latest filing, from $3.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.4 million in Q1 2024 and bottomed at -$3.4 million in Q2 2024.
• Historically, Change in Accured Expenses has averaged $1.2 million across 5 years, with a median of $1.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses sank 332.23% in 2023, then jumped 1226.23% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$545000.0 in 2022, then surged by 609.72% to $2.8 million in 2023, then surged by 67.6% to $4.7 million in 2024, then tumbled by 160.93% to -$2.8 million in 2025, then soared by 221.08% to $3.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.4 million, $3.9 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.